Source comparison
BPC-157 vs LL-37 for Wound Healing Research UK 2026
All peptide compounds referenced in this article are intended strictly for laboratory and academic research purposes. They are not approved for human use, therapeutic application, or clinical treatment. This content is directed at qualified researchers operati
This comparison does not assign a generated winner or score.
- All peptide compounds referenced in this article are intended strictly for laboratory and academic research purposes. They are not approved for human use, therapeutic application, or clinical treatment. This content is directed at qualified researchers operating within applicable UK regulatory frameworks (Research Use Only).
- BPC-157 and LL-37 are both extensively characterised for wound healing activity, yet they address fundamentally different aspects of the repair process. BPC-157 drives angiogenesis, fibroblast migration, tendon/ligament repair, and systemic tissue protection via FAK-eNOS-NO-VEGFR2 signalling — mechanistically oriented toward the vascular and fibroblastic components of healing. LL-37 drives antimicrobial defence, re-epithelialisation, innate immune cell recruitment, and keratinocyte proliferation — mechanistically oriented toward the epithelial and infectious components of the wound environment. Understanding this division is essential for designing experiments that cleanly attribute wound-healing outcomes to one versus the other pathway. This comparison is distinct from the TB-500 vs BPC-157 comparison (ID 77412), the BPC-157 pillar guide, and the LL-37 pillar guide.